| | Investigations | Result on admission | Results two weeks after the admission | Results four months after the admission |
| | WBC (/µl), (3500–9700) | 11530 | 7600 | 6800 | | Differential count (%) | N 47.0, L 27.0, M 3.0, A 23.0 | N 68.0, L 25.4, M 6.6, A 0 | N 60.5, L 34.9, M 4.6, A 0 | | Hemoglobin (g/dl), (11.2–15.2) | 12.4 | 12.2 | 12.5 | | Platelet count (×109/L), (14.9–37.9) | 22.2 | 30.3 | 23.1 | | CRP (mg/dl), (<0.3) | 3.34 | 0.04 | 0.04 | | HBV, HCV serology | Negative | | | | Serum HIV antibody | Negative | | Negative | | Blood HIV RNA | Negative | | | | AST (U/l), (8–38) | 116 | 20 | 21 | | ALT (U/l), (4–44) | 183 | 22 | 16 | | Glucose (mg/dl), (70–109) | 140 | 158 | 93 | | CSF counts (cells/mm3) | WBC 186 (N 6, L 180) | WBC 21 (N 0, L 21) | | | CSF glucose (mg/dl), (50–75) | 96 | 58 | | | CSF protein (mg/dl), (15–45) | 41 | 37 | | | CSF gram stain and culture | Negative | | | | CSF TB-PCR | Negative | | | | CSF fungal culture | Negative | | | | Nasopharynx influenza antigen (A and B) | Negative | | | | Nasopharynx COVID-19 RNA | Negative | | | | Blood CMV pp65 antigenemia (0 pp65-positive cells per 5 × 105 cells) | Positive (17) | Negative (0) | Negative (0) | | Blood CMV DNA | Positive (1.6 × 103 copies/ml) | Negative | | | CSF CMV DNA | Negative | | | | Serum anti-CMV IgM (<0.8 titers) | Positive (8.54) | Positive (7.49) | Positive (2.99) | | Serum anti-CMV IgG (<2.0 titers) | Positive (15.5) | Positive (71.0) | Positive (42.5) | | CSF HSV DNA | Negative | | | | Serum anti-HSV IgM (<0.8 titers) | Negative (0.28) | | | | Serum anti-HSV IgG (<2.0 titers) | Negative (<2.0) | | | | Blood EBV DNA | Positive (2.93 log IU/ml) | Negative | | | CSF EBV DNA | Negative | | | | Serum anti-EBNA IgG (<0.5 titers) | Positive (4.0) | Positive (3.1) | Positive (4.3) | | Serum anti-VCA-IgM (<0.5 titers) | Positive (12.7) | Positive (8.9) | Positive (1.4) | | Serum anti-VCA-IgG (<0.5 titers) | Positive (8.2) | Positive (8.3) | Positive (8.4) | | Serum anti-VZV IgM (<0.8 titers) | Positive (1.32) | Positive (1.48) | Negative (0.62) | | Serum anti-VZV IgG (<2.0 titers) | Positive (89.0) | Positive (74.0) | Positive (55.6) | | Serum antimumps IgM (<0.8 titers) | Positive (2.9) | Positive (2.58) | Borderline (0.82) | | Serum antimumps IgG (<2.0 titers) | Positive (47.0) | Positive (39.0) | Positive (23.5) | | Serum interleukin-6 (pg/ml), (<4) | 10.3 | 2.4 | |
|
|
Normal ranges are given in parentheses. WBC, white blood cell; N, neutrophils; L, lymphocytes; M, monocytes; A, atypical lymphocytes; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; CSF, cerebrospinal fluid; TB, tuberculosis; PCR, polymerase chain reaction; CMV, cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein–Barr virus; EBNA, Epstein–Barr virus nuclear antigen; VCA, virus capsid antigen; VZV, varicella-zoster virus; IgM, immunoglobulin M; IgG, immunoglobulin G.
|
